AstraZeneca AB — Sponsor Intelligence | 274 EU Trials

Filter these 274 trials by condition, phase, country and more.

Open in Search →

274 Registered trials

84 Recruiting

175 Completed trials

25 Countries active

204 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 129 Phase II/III: 2 Phase II: 56 Phase I/II: 13 Phase III/IV: 2 Phase IV: 3 Phase I: 12 Phase I (Other): 40 Phase I (FiH): 16 Other: 1

Oversight events:

10 serious breaches 32 temporary halts 5 urgent safety measures 1 unexpected event 6 corrective measures across 24 trials

View oversight register →

100%

175 of 175 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 13 Chronic obstructive pulmonary disease 11 Asthma 11 Chronic kidney disease 6 Systemic lupus erythematosus 5 Triple negative breast cancer 5 Non-small cell lung cancer metastatic 4 Hepatocellular carcinoma 4 Breast cancer 4 Ovarian cancer 4 Non-small cell lung cancer stage III 3 Prostate cancer metastatic 3

Top IMPs

DURVALUMAB 45 RILVEGOSTOMIG 20 TRASTUZUMAB DERUXTECAN 18 DATOPOTAMAB DERUXTECAN 17 OSIMERTINIB 16 INFLIXIMAB 15 MYCOPHENOLATE MOFETIL 15 VOLRUSTOMIG 12 OLAPARIB 11 TREMELIMUMAB 11 CAMIZESTRANT 8 CAPIVASERTIB 8

All trials — page 9

274 total

Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Phase III 12 countries OLAPARIB
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended

2024-511142-39-00 Phase III 5 countries OLAPARIB
An Open-label Study to check Safety, Tolerability and medication behaviour of a capsule with AZD6244 in Patients with Advanced Solid Maligna… Ended

2022-500685-10-00 Phase I (Other) 1 country
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-sta… Halted

2025-522551-25-00 Phase I (Other) 1 country
A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms Halted

2025-520786-44-00 Phase I (FiH) 1 country AZD2962
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL) Halted

2023-505840-20-00 Phase I/II 4 countries HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Phase III 11 countries CARBOPLATIN; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PACLITAXEL; PEMBROLIZUMAB; PEMET…
A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer Ended

2024-519044-32-00 Phase I/II 2 countries SARUPARIB
A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors Ended

2024-513692-41-00 Phase I (Other) 2 countries
A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how m… Ended

2024-518467-35-00 Phase I (Other) 1 country
A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR… Ended

2024-516699-14-00 Phase I (FiH) 5 countries AZD0022; CETUXIMAB
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab Ended

2024-511840-22-00 Phase I (Other) 1 country
A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess the Safety, Tolerability, and Pharmacodyna… Ended

2024-519414-31-00 Phase I (Other) 1 country
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4… Ended

2024-516840-24-00 Phase I (Other) 3 countries
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes M… Ended

2024-512562-34-00 Phase II 5 countries AZD5004; SEMAGLUTIDE
A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone Ended

2024-516176-15-00 Phase II 1 country AZD6234; AZD9550
A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharma… Ended

2024-516474-30-00 Phase I (Other) 1 country
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adu… Ended

2024-514213-35-00 Phase I (Other) 1 country
Effects of AZD5004 in adults who are living with obesity or overweight with at least 1 weight-related medical condition Ended

2024-513691-18-00 Phase II 1 country AZD5004
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants with Renal Impairment Ended

2024-514359-14-00 Phase I (Other) 1 country
A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Parti… Ended

2024-513848-28-00 Phase I (Other) 2 countries
A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With… Ended

2024-513143-82-00 Phase I (Other) 1 country AZD3427; DOPAMINE HYDROCHLORIDE; O15-WATER; SODIUM CHLORIDE
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers. Ended

2023-506997-11-00 Phase I 3 countries
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin… Ended

2024-513142-11-00 Phase I (Other) 2 countries

Showing 193–216 of 274 trials

← All sponsors A–Z